ARTICLE | Clinical News
Angiochem preclinical data
December 15, 2014 8:00 AM UTC
In mice bearing intracranial HER2-positive tumors, twice-weekly 15 mg/kg IV ANG4043 significantly improved median overall survival (OS) vs. vehicle-treated controls (80 vs. 45 days, p=0.0003). Data we...